Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (Nasdaq: PSNL) reported Q4 2021 revenue of $20.7 million, a 3% increase from Q4 2020. Revenue from biopharma customers, excluding the VA MVP, surged 102% to $15.4 million. However, revenue from the VA MVP fell 58% to $5.3 million. For the full year, revenue reached $85.5 million, a 9% increase. Operating expenses were $28.2 million in Q4, leading to a net loss of $20.2 million. The company forecasts $67.0 million in revenue for 2022, with a net loss between $110.0 million and $115.0 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, announced that its management will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 p.m. Eastern Time. The company specializes in providing precision cancer therapies and diagnostics through its Personalis NeXT Platform, offering insights into all human genes and the immune system from a single sample. The clinical laboratory is highly accredited, emphasizing quality and efficiency.
Personalis, Inc. (NASDAQ: PSNL) announced a strategic partnership with the Moores Cancer Center at UC San Diego Health to enhance clinical diagnostic testing for patients with advanced tumors. This collaboration aims to utilize Personalis' advanced genomic tumor profiling test to inform FDA-approved therapy decisions and clinical trial options. The partnership also focuses on developing novel biomarkers and conducting research on a liquid biopsy assay that significantly improves sensitivity for detecting minimal residual disease and cancer recurrence, enhancing patient care.
Personalis, Inc. (NASDAQ: PSNL) announced that it will release its fourth quarter and full-year 2021 financial results on February 24, 2022. A conference call and webcast will follow at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results and recent highlights. Interested parties can access the call via telephone or through the company's website. Personalis specializes in advanced cancer genomics, offering the Personalis NeXT Platform, which provides insights into approximately 20,000 human genes.
Personalis, Inc. (NASDAQ: PSNL), a leader in advanced cancer genomics, announced its management team will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 2:00 p.m. Eastern Time. The event will be accessible via a webcast link for attendees. Personalis is known for its Personalis NeXT Platform®, which provides comprehensive genomic information from tissue samples, facilitating precision cancer therapies and diagnostics. The lab is CLIA certified and CAP accredited, ensuring clinical accuracy and efficiency.
Personalis, Inc. (PSNL) announced preliminary revenue estimates for Q4 and the full year of 2021, reporting approximately $20.7 million for Q4 and $85.5 million for the full year. Revenue from biopharma customers reached $15.4 million in Q4 2021, reflecting a 102% increase year-over-year. However, revenue from the U.S. Department of Veterans Affairs Million Veterans Program fell 58% to $5.3 million in Q4 and decreased 19% for the year. The company holds an estimated $287 million in cash as of December 31, 2021.
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, will present at the 24th Annual Needham Virtual Growth Conference on January 11, 2022. The company's innovative Personalis NeXT Platform® provides comprehensive genomic insights from tissue samples, aiding in precision oncology. Furthermore, Personalis is a key provider for Veterans Affairs' Million Veteran Program, reinforcing its position in population sequencing. The firm's lab emphasizes clinical accuracy with necessary certifications, ensuring top-tier service in advanced cancer diagnostics.
Personalis, Inc. (NASDAQ: PSNL) announced the launch of NeXT Personal, a next-generation tumor-informed liquid biopsy assay that enhances detection of molecular residual disease (MRD) with a sensitivity down to 1 part-per-million. This marks a 10- to 100-fold improvement over existing technologies, enabling earlier detection across various cancers, including challenging low mutational burden and early-stage cancers. NeXT Personal creates a tailored liquid biopsy panel from a patient’s tumor to better monitor cancer treatment.
Personalis, Inc. (NASDAQ: PSNL) announced participation in the 33rd Annual Piper Sandler Virtual Healthcare Conference on December 1, 2021. This event showcases Personalis' leadership in advanced cancer genomics aimed at precision cancer therapies. Interested parties can access a pre-recorded webcast of the presentation for 90 days through their website. Personalis’ NeXT Platform® supports comprehensive genomic insights from tissue samples, enhancing diagnostics for biopharmaceutical customers. For further details, visit investors.personalis.com.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
